Furthermore, in a study by Grohmann et al., patients affected by SMH secondary to AMD were also treated in a similar manner, receiving a triple injection of 20 μg rtPA, 1.25 mg Bevacizumab, and 0.3 mL (16%) hexafluoroethane (C2F6) gas, followed by a prone positioning protocol, with additional anti-VEGF injections administered in cases of persistent macular edema [19]. The gene discussed is VEGFA; the disease is age-related macular degeneration.